ITAP 6-month results of a prospective, randomised phase 3 study for evaluation of the combination therapy of PDT and intravitreal triamcinolone in exudative AMD;ITAP 6-Monats-Ergebnisse einer prospektiven und randomisierten Phase-3-Studie zur Evaluation der Kombinationstherapie aus PDT und intravitrealem Triamcinolon bei der exsudativen AMD

Klinische Monatsblatter fur Augenheilkunde

Volumn 226, Issue 1, 2009, Pages 60-65

  Gamulescu, M A ^a   Schubert, K ^a   Thormann, S ^b   Attaran, M ^c   Dueck, N ^d   Wiechens, B ^c   Spital, G ^d   Stroux, A ^b   Wachtlin, J ^b,e  

^a Ophthalmologie   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Augenklinik Nordstadt   (Germany)

^d ST FRANZISKUS HOSPITAL   (Germany)

^e Sankt Gertrauden Krankenhaus   (Germany)

Author keywords

Age related macular degeneration; Intravitreal injection; Photodynamic therapy; Randomised study; Retina; Triamcinolone

Indexed keywords

TRIAMCINOLONE ACETONIDE; ANTIINFLAMMATORY AGENT; TRIAMCINOLONE;

AGED; ARTICLE; CATARACT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY; PHASE 3 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; RANDOMIZED CONTROLLED TRIAL; RETINA; RETINA MACULA AGE RELATED DEGENERATION; RETREATMENT; SCORING SYSTEM; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; DRUG EFFECT; EXUDATE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PHOTOCHEMOTHERAPY; RETINA MACULA DEGENERATION; TREATMENT OUTCOME; VITREOUS BODY;

AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; CHOROIDAL NEOVASCULARIZATION; COMBINED MODALITY THERAPY; EXUDATES AND TRANSUDATES; FEMALE; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; TREATMENT OUTCOME; TRIAMCINOLONE; VITREOUS BODY;

EID: 64349096400     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1027729     Document Type: Article

References (32)

1. Arias L, Garcia-Arumi J, Ramon J M. et al. Photodynamic therapy with intravitreal triaminolone in predominantly classic choroidal neovascularization: one-year results of a randomized study. Ophthalmology 2006 113 (12) 2243-2250
2. Augustin A J., Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006 113 (1) 14-22
3. Brown D M., Kaiser P K., Michels M et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006 355 1432-1444
4. Chan W M., Lai T Y., Wong A L. et al. Combined photodynamic therapy and intravitreal triamcinolone acetonide for the treatment of subfoveal choroidal neovascularization in age-related macular degeneration: a comparative study. Br J Ophthalmol 2006 90 (3) 337-341
5. Chandler D B., Rozakis G, Juan E de et al. The effect of triamcinolone acetonide on a refined experimental model of proliferative vitreoretinopathy. Am J Ophthalmol 1985 99 686-690
6. Chaudhary V Jr, Mao A, Hooper P L. et al. Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: a prospective randomized trial. Ophthalmology 2007 114 (12) 2183-2189
7. Florman N, Zor U. Mechanism of steroid action in ocular inflammation: Inhibition of prostaglandin production. Invest Opthalmol Vis Sci 1977 16 (1) 69-73
8. Gillies M C., Simpson J M., Luo W et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol 2003 121 (5) 667-673
9. Gragoudas E S., Adamis A P., Cunningham E T. et al. VEGF Inhibition Study in Ocular Nevascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004 351 (27) 2805-2816
10. Hahn R Jr, Sacu S, Michels S et al. Intravitreal bevacizumab versus verteporfin and intravitreal triamcinolone acetonide in patients with neovascular age-related macular degeneration. Ophthalmologe 2007 104 (7) 588-593
11. Ishibashi T, Miki K, Sorgente N et al. Effects of intravitreal administration of steroids on experimental subretinal neovascularization in the subhuman primate. Arch Ophthalmol 1985 103 708-711
12. Jaissle G B., Szurman P, Barzt-Schmidt K U. Nebenwirkungen und Komplikationen der intravitrealen Triamcinolonacetonid-Therapie. Ophthalmologe 2004 101 121-128
13. Jaissle G B., Szurman P, Bartz-Schmidt K U. et al. Recommendation for the implementation of intravitreal injections statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA). Klin Monatsbl Augenheilkd 2005 222 (5) 390-395
14. Jonas J B., Hayler J K., Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative vitreoretinopathy. Br J Ophthalmol 2000 84 (9) 1064-1067
15. Jonas J B., Degenring R F., Kreissig I et al. Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study. Eye 2005 19 (2) 163-170
16. Kaiser for the TAP-Study Group K. Verteporfin therapy of subfoveal horoidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP Report no. 8. Graefes Arch Clin Exp Ophthalmol 2006 244 (9) 1132-1142
17. Kvanta A, Algvere P V., Berglin L et al. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996 37 1929-1934
18. Lee J, Freeman W R., Azen S P. et al. Prospective, randomized clinical trial of intravitreal triamcinolone treatment of neovascular age-related macular degeneration: one-year results. Retina 2007 27 (9) 1205-1213
19. Penfold P L., Gyory J F., Hunyor A B. et al. Exudative macular degeneration and intravitreal triamcinolone. A pilot study. Aust N Z J Ophthalmol 1995 23 (4) 293-298
20. Penfold P L., Wen L, Madigan M C. et al. Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the EVC304 cell line: implications for macular degeneration. Clin Exp Immunol 2000 121 (3) 458-465
21. Rosenfeld P J., Brown D M., Heier J S. et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006 355 1419-1431
22. Schadlu R, Kymes S M., Apte R S. Combined photodynamic therapy and intravitreal triamcinolone for neovascular age-related macular degeneration: effect of initial visual acuity on treatment response. Graefes Arch Clin Exp Ophthalmol 2007 245 (11) 1667-1672
23. Spaide R F., Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2003 110 (8) 1517-1525
24. Spaide R F., Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005 112 (2) 301-304
25. Spaide R F., Laud K, Fine H F. et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006 26 383-390
26. Tano Y, Chandler D, Machemer R. Treatment of intraocular proliferation with intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 1980 90 (6) 810-816
27. Tatar O, Adam A, Shinoda K et al. Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy. Am J Ophthalmol 2006 142 (1) 95-104
28. Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year-results of 2 randomized clinical trials TAP report 1. Arch Ophthalmol 1999 117 1329-1345
29. Verteporfin in photodynamic therapy study group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization Verteporfin in Photodynamic Therapy report 2. Am J Ophthalmol 2001 131 541-560
30. Visudyne in minimally classic choroidal neovascularization study group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005 123 448-457
31. Weigert G, Michels S, Sacu S et al. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br J Ophthalmol 2008 92 (3) 356-360
32. Wilson C A., Berkowitz B A., Sato Y et al. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol 1992 110 (8) 1155-1159